CAR-T hospitalization characteristics by cardiac events
| . | No cardiac events (N = 67) . | Cardiac events (N = 11) . | P . |
|---|---|---|---|
| Maximum CRS gr 2 or above | 10 (14.9%) | 6 (54.5%) | .009 |
| Maximum CRS grade | |||
| 0 | 15 (22.4%) | 0 (0.0%) | |
| 1 | 42 (62.7%) | 5 (45.5%) | |
| 2 | 10 (14.9%) | 4 (36.4%) | |
| 3 | 0 (0.0%) | 0 (0.0%) | |
| 4 | 0 (0.0%) | 1 (9.1%) | |
| 5 | 0 (0.0%) | 1 (9.1%) | |
| Day of CRS onset after CAR-T | 1.5 ± 2.4 | 0.7 ± 0.6 | .043 |
| Day of maximum CRS after CAR-T | 1.8 ± 2.6 | 1.3 ± 1.4 | .383 |
| Duration of CRS in days | 2.5 ± 1.8 | 2.5 ± 1.6 | .978 |
| Maximum ICANS gr 3 or above | 3 (4.5%) | 3 (27.3%) | .043 |
| Maximum ICANS | .005 | ||
| 0 | 59 (88.1%) | 7 (63.6%) | |
| 1 | 3 (4.5%) | 0 (0.0%) | |
| 2 | 2 (3.0%) | 1 (9.1%) | |
| 3 | 3 (4.5%) | 1 (9.1%) | |
| 4 | 0 (0.0%) | 2 (18.2%) | |
| CAR-T dose | 1 | ||
| Less than 400 million | 22 (33.8%) | 4 (36.4%) | |
| More than 400 million | 43 (66.2%) | 7 (63.6%) | |
| Length of stay in days | 9.4 ± 3.9 | 22.0 ± 23.3 | .104 |
| ICU admission | 1 (1.5%) | 3 (27.3%) | .004 |
| Tocilizumab use | 48 (71.6%) | 11 (100.0%) | .099 |
| Steroid use | 18 (26.9%) | 9 (81.8%) | .001 |
| Anakinra use | 0 (0.0%) | 2 (18.2%) | .012 |
| Tocilizumab day after CRS onset | .720 | ||
| 0 d | 33 (70.2%) | 7 (62.6%) | |
| 1 d | 11 (23.4%) | 4 (36.4%) | |
| 2-3 d | 3 (6.4%) | 0 (0%) | |
| Maximum CRP (μg/mL) | 9.3 ± 8.0 | 10.2 ± 8.4 | .728 |
| Maximum ferritin (ng/mL) | 3 410.3 ± 5 441.9 | 10 165.5 ± 13 431.3 | .129 |
| Troponin level, day 5 (ng/mL) | 0.0 ± 0.0 | 0.2 ± 0.5 | .277 |
| BNP level, day 5 (pg/mL) | 100.8 ± 171.6 | 1 105.9 ± 1 370.5 | .059 |
| . | No cardiac events (N = 67) . | Cardiac events (N = 11) . | P . |
|---|---|---|---|
| Maximum CRS gr 2 or above | 10 (14.9%) | 6 (54.5%) | .009 |
| Maximum CRS grade | |||
| 0 | 15 (22.4%) | 0 (0.0%) | |
| 1 | 42 (62.7%) | 5 (45.5%) | |
| 2 | 10 (14.9%) | 4 (36.4%) | |
| 3 | 0 (0.0%) | 0 (0.0%) | |
| 4 | 0 (0.0%) | 1 (9.1%) | |
| 5 | 0 (0.0%) | 1 (9.1%) | |
| Day of CRS onset after CAR-T | 1.5 ± 2.4 | 0.7 ± 0.6 | .043 |
| Day of maximum CRS after CAR-T | 1.8 ± 2.6 | 1.3 ± 1.4 | .383 |
| Duration of CRS in days | 2.5 ± 1.8 | 2.5 ± 1.6 | .978 |
| Maximum ICANS gr 3 or above | 3 (4.5%) | 3 (27.3%) | .043 |
| Maximum ICANS | .005 | ||
| 0 | 59 (88.1%) | 7 (63.6%) | |
| 1 | 3 (4.5%) | 0 (0.0%) | |
| 2 | 2 (3.0%) | 1 (9.1%) | |
| 3 | 3 (4.5%) | 1 (9.1%) | |
| 4 | 0 (0.0%) | 2 (18.2%) | |
| CAR-T dose | 1 | ||
| Less than 400 million | 22 (33.8%) | 4 (36.4%) | |
| More than 400 million | 43 (66.2%) | 7 (63.6%) | |
| Length of stay in days | 9.4 ± 3.9 | 22.0 ± 23.3 | .104 |
| ICU admission | 1 (1.5%) | 3 (27.3%) | .004 |
| Tocilizumab use | 48 (71.6%) | 11 (100.0%) | .099 |
| Steroid use | 18 (26.9%) | 9 (81.8%) | .001 |
| Anakinra use | 0 (0.0%) | 2 (18.2%) | .012 |
| Tocilizumab day after CRS onset | .720 | ||
| 0 d | 33 (70.2%) | 7 (62.6%) | |
| 1 d | 11 (23.4%) | 4 (36.4%) | |
| 2-3 d | 3 (6.4%) | 0 (0%) | |
| Maximum CRP (μg/mL) | 9.3 ± 8.0 | 10.2 ± 8.4 | .728 |
| Maximum ferritin (ng/mL) | 3 410.3 ± 5 441.9 | 10 165.5 ± 13 431.3 | .129 |
| Troponin level, day 5 (ng/mL) | 0.0 ± 0.0 | 0.2 ± 0.5 | .277 |
| BNP level, day 5 (pg/mL) | 100.8 ± 171.6 | 1 105.9 ± 1 370.5 | .059 |
Data are presented as mean ± SD, median (interquartile range), or number (percentage), depending on type of data.
P < .05 is bolded.
gr, grade; ICU, intensive care unit.